SBIR/STTR Research Award

Transmucosal oral diphenhydramine-rapid relief of nausea

Award identifier dbc4a495df0d44303172abadc09313081b69719298c9cbebbec7783e7bcd9bf9Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$185,654

Program and phase

SBIR · Phase I

Award year

2001

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
PINNEY ASSOCIATES
Proposal award date
Not reported
Contract end date
Not reported
UEI
Not reported
Solicitation number
Not reported
Topic code
Not reported

Research abstract

DESCRIPTION (Provided by the applicant): Development of a transmucosal oral gum (TOG) delivery system is proposed for diphenhydramine, a first-line antiemetic for treatment of nausea, including patients with HIV disease. Although many antiemetics are available for use, nearly all are administered by oral ingestion with slow onset of effects. A buffered TOG delivery system will provide advantages over existing medications including: a) rapid delivery of diphenhydramine into the bloodstream followed by sustained release, providing early and lasting nausea relief; b) avoidance of first-pass effects; c) improved bioavailability; d) user control over dosing; and e) convenience of use. Transmucosal systems invented by this research team with demonstrated efficacy will be adapted for diphenhydramine. Standardized, in vitro, mechanical gum chewing methodology and a validated HPLC assay will be used in dissolution studies to optimize performance. Gum prototypes targeted for medication release necessary for rapid and sustained nausea relief will be developed. Optimization of a diphenhydramine TOG delivery system will allow for future assessment in humans and subsequent commercialization. A safe and effective TOG medication, available over-the-counter, with a rapid onset and sustained action will improve nausea treatment significantly. PROPOSED COMMERCIAL APPLICATION: The need for medication delivery systems capable of rapid relief of nausea is considerable. For people with HIV disease, nausea and vomiting are often side effects of medications or symptoms of an underlying illness. Although many antiemetics are available for use, nearly all ere administered by oral ingestion with slow onset of effects. The proposed oral transmucosal delivery of diphenhydramine by a buffered gum would provide an innovative means of rapid and sustained, safe, and effective over-the-counter treatment of nausea. A large commercial market exists for treatment of nausea in adults, especially for those suffering with HIV disease.

Technology keywords

Not reported

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.